Key result
PFO closure is evaluated against antiplatelet therapy for 5-year recurrent stroke risk.
Key points are not available for this paper at this time.
Answers are grounded in this paper and cite their sources.
Extended 5-Year Follow-up of the PFO Closure Trial In the initial report of the Gore REDUCE trial of patent foramen ovale closure, with a median follow-up of 3.2 years, 18 patients had stroke recur...
No takes yet. Share an insight, caveat, or question.
Kasner et al. (2021) studied this question. Patent foramen ovale closure versus antiplatelet therapy was evaluated for 5-year stroke recurrence after an initial 3.2-year follow-up with 18 recurrent strokes.
Synapse has enriched 10 related papers. Consider them for comparative context: